ObjectiveTo investigate the clinical application efficacy of BD regimen combined with cyclophosphamide and pirarubicin in treatment of patients with refractory multiple myeloma. MethodsA total of 70 cases of refractory multiple myeloma patients were selected and divided into observation group and control group according to random number table method,with 35 cases in each group.The control group was received BD regimen on the basis of supportive care,while the observation group was combined cyclophosphamide and pirarubicin treatment on the basis of the therapeutic method of control group.28 days as one course of treatment,After 4 courses treatment,the total response rate (ORR), incidence of adverse reactions, overall survival and mean survival time were compared between two groups. ResultsThe ORR of observation group (85.71%) was significantly higher thancontrol group (62.86%),with statistical significance (P＜0.05).The total infective incidence of observation group (40.0%) was significantly higher than control group (17.1%) ,the total incidence of gastrointestinal reactions of observation group (37.14%) was significantly higher than control group (14.29%) ,with statistical significance (P＜0.05).However,all patients could be tolerated and relieved after treatment,without affecting the treatment.Kaplan-meier survival analysis indicated that the mean survival time in observation group was (22.84±4.22) months,(20.78±3.61) months in control group,the difference was statistically significant (P＜0.05). ConclusionThe BD regimen combination with cyclophosphamide and pirarubicin in treatment of refractory multiple myeloma can improve the efficacy and extend overall survival of patients,which is well tolerated and worthy of promoting.

无